Citations 1
Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study
Muffly, Lori , Frey, Noelle V. , Roloff, Gregory W. , Park, Jae H, Advani, Anjali S. , Bachanová, Veronika , Cassaday, Ryan D. , Daunov, Michael , Dykes, Kaitlyn C. , Gatell, Vivian Irizarry , Jamy, Omer , Kota, Vamsi, Kumaran, Muthu, O’Dwyer, Kristen M. , Oliai, Caspian , Schwartz, Marc S., Solh, Melhem M., Stock, Wendy, Tsai, Stephanie B., Ulrickson, Matthew L., Vasu, Sumithira, Leonard, Jessica T., Aldoss, Ibrahim, Dholaria, Bhagirathbhai R , Advani, Anjali S , Cassaday, Ryan D , Daunov, Michael , Dykes, Kaitlyn C , Grunwald, Michael , Hilal, Talal , Hill, LaQuisa C , Jamy, Omer , Lin, Chenyu , Logan, Aaron C , Luskin, Marlise R , O'Dwyer, Kristin , Oliai, Caspian H , Oluwole, Olalekan O , Sasine, Joshua , Wang, Eunice S. , Strickland, Stephen Anthony , Leonard, Jessica T , Shah, Bijal , Bachanova, Veronika , Muffly, Lori , Frey, Noelle V , Roloff, Gregory W , Dholaria, Bhagirathbhai , Grunwald, Michael R. , Hilal, Talal , Hill, LaQuisa C. , Kota, Vamsi , Oluwole, Olalekan O. , Sasine, Joshua , Solh, Melhem , Stock, Wendy , Tsai, Dr. Stephanie B., Ulrickson, Matthew L. , Vasu, Sumithira , Yalniz, Fevzi , Shah, Bijal , Aldoss, Ibrahim
Blood | May 19, 2026 | Volume: 148 | Issue: 6 | Pages: 657-668
Abstract The use of chimeric antigen receptor (CAR) T-cell therapy is increasing for adult B-cell acute lymphoblastic leukemia (B-ALL), with 3 CD19 CAR T-cell products commercially available. Several key clinical questions related to best practices for CAR T-cell administration in this population exist, and limited prospective randomized trials have been conducted to fill these knowledge gaps. Thus, to help guide clinical practice, we conducted a modified Delphi study to develop and validate consensus recommendations on the administration of commercially available CAR T-cell therapy for adults with B-ALL. Consensus panelists (n = 9) included principal investigators (PIs) from Real World Outcomes Collaborative of CAR T-Cell Therapy in Adult ALL (ROCCA) consortium sites and were selected based on expertise and CAR T-cell center volume. Final panel consensus recommendations were distributed for rating by the remaining PIs from ROCCA consortium sites, which served as the validation group (n = 27). Consensus topics included patient selection, bridging and pre–CAR T-cell leukemia staging, lymphodepletion, and CAR T-cell treatment setting, specific toxicity prevention and management, post–CAR T-cell response assessment and disease monitoring, and the role of consolidation and/or maintenance therapies after CAR T-cell therapy. Initially, 58 recommendation statements were evaluated for consensus. After 2 panel meetings, a total of 34 statements achieved consensus rating among the expert panel. After rating by the validation group, all but 1 recommendation statement continued to meet consensus, for a total of 33 consensus recommendation statements on the administration of CAR T-cell therapy in adult B-ALL.